Blog
RSS FeedPosted by Michael Wonder on 08 Aug 2023
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries
8 August 2023 - Managed entry agreements continue to emerge in health technology assessment based decision-making, to address evidentiary uncertainties arising ...
Posted by Michael Wonder on 18 Jun 2021
Efficient funding of chemotherapy review - submissions on discussion paper
18 June 2021 - The efficient funding of chemotherapy review discussion paper was released on 21 May 2021 to gain ...
Posted by Michael Wonder on 26 Aug 2020
Agenda for the November 2020 PBAC meeting
26 August 2020 - The agenda for the November 2020 PBAC meeting is now available. ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...
Posted by Michael Wonder on 05 Aug 2016
PBAC post-market reviews of chronic obstructive pulmonary disease medicines and ezetimibe
5 August 2016 - The public submission process is now closed. ...
Posted by Michael Wonder on 04 Jan 2016
Expanded PBS Safety Net early supply arrangements apply from 1 January 2016
4 January 2016 - Measures announced as part of the PBS Access and Sustainability package include expanding Safety Net early supply ...
Posted by Michael Wonder on 21 Aug 2015
Meet the health crusader saving lives with cheap drugs
20 August 2015 - A Tasmanian man with hepatitis C is taking on a global pharmaceutical company for what he says ...